Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC

SIMPLE SUMMARY: Targeted therapy has revolutionized the treatment of non-small cell lung cancer (NSCLC) and MET inhibition is a promising therapy for MET-dysregulated NSCLC. However, due to the lack of effective biomarkers, the clinical efficacy is unsatisfactory. This study aims to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Jie, Guang-Ling, Peng, Lun-Xi, Zheng, Mei-Mei, Sun, Hao, Wang, Song-Rong, Liu, Si-Yang Maggie, Yin, Kai, Chen, Zhi-Hong, Tian, Hong-Xia, Yang, Jin-Ji, Zhang, Xu-Chao, Tu, Hai-Yan, Zhou, Qing, Wong, Catherine C. L., Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818927/
https://www.ncbi.nlm.nih.gov/pubmed/36612298
http://dx.doi.org/10.3390/cancers15010302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818927/
https://www.ncbi.nlm.nih.gov/pubmed/36612298
http://dx.doi.org/10.3390/cancers15010302

Ejemplares similares